pyrazines has been researched along with n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Burns, CJ; Khong, T; Monaghan, KA; Spencer, A | 1 |
1 other study(ies) available for pyrazines and n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
Article | Year |
---|---|
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-6; Janus Kinase 1; Melphalan; Multiple Myeloma; Phosphorylation; Pyrazines; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Stromal Cells | 2011 |